Research network involvement and addiction treatment center staff: Counselor attitudes toward buprenorphine

American Journal on Addictions

Volumn 16, Issue 5, 2007, Pages 365-371

  Knudsen, Hannah K ^a,b   Ducharme, Lori J ^a   Roman, Paul M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; COUNSELING; EVIDENCE BASED PRACTICE; HUMAN; OUTCOME ASSESSMENT; PRIVATE HOSPITAL; PUBLIC HEALTH SERVICE; TECHNOLOGY;

ADULT; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; BUPRENORPHINE; COUNSELING; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; SUBSTANCE-RELATED DISORDERS;

EID: 34548831702     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490701525418     Document Type: Article

References (38)

1. Institute of Medicine. Bridging the Gap between Practice and Research: Forging Partnerships with Community-Based Drug and Alcohol Treatment. Washington, DC: National Academy Press; 1998.
2. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001;61:195-206.
3. Rosenheck R, Kosten T. Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend. 2001;63:253-262.
4. Hanson GR, Leshner AI, Tai B. Putting drug abuse research to use in real-life settings. J Subst Abuse Treat. 2002;23:69-70.
5. National Institute on Drug Abuse. National Drug Abuse Treatment Clinical Trials Network. Available at: http://www.nida.nih.gov/CTN/protocol/brochure/ 2005_ctn_brochure%2010_17_05.pdf. Accessed on August 24, 2006.
6. Saxon AJ, McCarty D. Challenges in the adoption of new pharmacotherapies for addiction to alcohol and other drugs. Pharmacol Ther. 2005;108:119-128.
7. Reback CJ, Cohen AJ, Freese TE, Shoptaw S. Making collaboration work: key components of practice/research partnerships. J Drug Issues. 2002;32:837-848.
8. Polcin D. Bridging psychosocial research and treatment in community substance abuse treatment programs. Addiction Research and Theory. 2004;12:275-283.
9. Arfken CL, Agius E, Dickson MW, Anderson HL, Hegedus AM. Clinicians beliefs and awareness of substance abuse treatments in research-and nonresearch-affiliated programs. J Drug Issues. 2005;35:547-558.
10. Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100:1090-1100.
11. Peirce JM, Petry NM, Stitzer ML, et al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment. Arch Gen Psychiatry. 2006;63:201-208.
12. Petry NM, Peirce JM, Stitzer ML, et al. Effect of prize-based incentives in outcomes in stimulant abusers in outpatient psychosocial treatment programs. Arch Gen Psychiatry. 2005;62:1148-1156.
13. Carroll KM, Ball SA, Nich C, et al. Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study. Drug Alcohol Depend. 2006;81:301-312.
14. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70:S13-S27.
15. Ling W, Smith D. Buprenorphine: blending practice and research. J Subst Abuse Treat. 2002;23:87-92.
16. Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 2003;70:S49-S57.
17. Fudula PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958.
18. Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction. 2002:97;1395-1404.
19. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343:1290-1297.
20. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60:39-50.
21. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1024-1030.
22. Amass L, Ling W, Freese TE, et al. Bringing buprenorphinenaloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict. 2004;13:S42-S46.
23. National Drug Abuse Treatment Clinical Trials Network. Buprenorphine/ naloxone-facilitated rehabilitation for opioid addicted adolescents/young adults (CTN 0010). Available at: http://www.nida.nih.gov/CTN/protocol/0010.html. Accessed on August 25, 2006.
24. Klein KJ, Sorra JS. The challenge of innovation implementation. Acad Manage Rev. 1996;21:1055-1080.
25. Rogers EM. The Diffusion of Innovations. 4th ed. New York: Free Press; 1995.
26. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md.: Substance Abuse and Mental Health Services Administration; 2004.
27. West JC, Kosten TR, Wilk J, et al. Challenges to increasing access to buprenorphine treatment for opiate addiction. Am J Addict. 2004;13:S8-S16.
28. Knudsen HK, Ducharme LJ, Roman PM, Link T. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005;29:95-106.
29. Thomas CP, Wallack SS, Lee S, McCarty D, Swift R. Research to practice: adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat. 2003;24:1-11.
30. Simpson DD. A conceptual framework for transferring research to practice. J Subst Abuse Treat. 2002;22:171-182.
31. Mulligan DH, McCarty D, Potter D, Krakow M. Counselors in public and private alcoholism and drug abuse treatment programs. Alcohol Treat Q. 1989;6:75-89.
32. Damanpour F. Organizational innovation: a meta-analysis of effects of determinants and moderators. Acad Manage J. 1991;34:555-590.
33. Mee-Lee DL, Gartner L, Miller MM, Shulman GD, Wilford BB. Patient Placement Criteria for the Treatment of Substance-Related Disorders. 2nd ed. Chevy Chase, Md.: ASAM; 1996.
34. Knudsen HK, Johnson JA, Roman PM. Retaining counseling staff at substance abuse treatment centers: effects of management practices. J Subst Abuse Treat. 2003:24;129-135.
35. Forman RF, Bovasso G, Woody G. Staff beliefs about addiction treatment. J Subst Abuse Treat. 2001;21:1-9.
36. Mark T, Kranzler HR, Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend. 2003;71:219-228.
37. Kasarabada ND, Hser YI, Parker L, Hall E, Anglin MD, Chang E. A self-administered instrument for assessing therapeutic approaches of drug-treatment counselors. Subst Use Misuse. 2001;36:273-299.
38. Institute of Medicine. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academy Press; 2003.